Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine depot - Alar Pharmaceuticals

Next Previous
Drug Profile

Ketamine depot - Alar Pharmaceuticals

Alternative Names: ALA-3000; Depot ketamine formulation - Alar Pharmaceuticals

Latest Information Update: 16 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alar Pharmaceuticals
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; Biogenic amine uptake modulators; Dopamine receptor agonists; Nicotinic receptor modulators; NMDA receptor antagonists; Opioid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Treatment-resistant depressive disorder

Most Recent Events

  • 30 Dec 2025 Alar Pharmaceuticals completes a phase I trial in Treatment resistant depressive disorders in USA (SC) (NCT06965569)
  • 21 Apr 2025 Phase-I clinical trials in Treatment resistant depressive disorders in USA (SC) (NCT06965569)
  • 21 Aug 2023 ALA 3000 receives Notice of Eligibility of Grant in Singapore (Alar Pharmaceuticals website, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top